Thomas Lingelbach | President and Chief Executive Officer

Thomas Lingelbach, President and Chief Executive Officer, Valneva

Following the Intercell-Vivalis merger, Thomas Lingelbach was appointed President & CEO of Valneva. He has been with Intercell since 2006, serving as COO until 2011 and since then as CEO. He has held a variety of positions of increasing international responsibility in his more than 20 years in the pharma and vaccine industry. He joined Intercell from Novartis Vaccine & Diagnostics as Managing Director Germany focusing on the integration with Chiron Vaccine where he served as Vice President Global Industrial Operations and Managing Director Chiron-Behring. Thomas Lingelbach holds a Master's degree in Engineering and complemented his education with a Business Administration program.


DC Co-conference Day 2 April 4 @ 3:40

Development of a novel prophylactic vaccine for the prevention of Lyme disease: Phase I results of Valneva’s Lyme vaccine candidate VLA15 and development outlook

  • Background and medical need
  • Vaccine design including preclinical data for VLA15        
  • Phase I results and development outlook

back to speakers